Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades

Vogler, Sabine; Windisch, Friederike; Knoll, Verena; Kieslich, Katharina (2026): Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades. Journal of Pharmaceutical Policy and Practice, 19 (1). https://doi.org/10.1080/20523211.2026.2670697

Full text not available from this repository.
Official URL (please open in a new browser tab/window): https://doi.org/10.1080/20523211.2026.2670697

Abstract

Background
In 2005, the Pharmaceutical Pricing and Reimbursement Information (PPRI) network of public authorities was established to offer a platform for information exchange among authorities responsible for pharmaceutical pricing and reimbursement. The article reviews the evolution of PPRI over its twenty years of existence and aims to identify its contributions to policymakers and the research community as well as areas for future development.

Methods
Based on a framework of structure, process and outcome indicators, adapted from the Donabedian Model, the article examines developments regarding membership in terms of geographic and thematic scope, governance, procedures for intra-network exchange of information as well as stakeholder engagement, and outcomes in terms of scientific output and spin-off activities. The review was informed by grey and peer-reviewed literature as well as unpublished information within the PPRI network.

Results
The PPRI network has evolved from a European group into a global network, comprising approximately 80 public authorities in pharmaceutical pricing and reimbursement from 50 countries. Its thematic focus remains pricing and reimbursement policies, and additionally, the PPRI network addressed several related topics. In 2018, a sub-group on medical devices (PPRI MD) was established. PPRI mainly serves its members by facilitating informed discussion at face-to-face and online meetings, and through internal queries on timely and policy-related topics. PPRI-sourced data has been published, including country information such as PPRI Pharma Profiles and Briefs, and scientific studies based on cross-country analyses. PPRI conferences offer an opportunity for disseminating scientific output and engaging with stakeholders.

Conclusion
PPRI is a network that has proven its value to policymakers by fostering information exchange as well as by producing reliable and relevant evidence. Success factors identified include a robust governance structure with clear responsibilities, a dedicated Secretariat as a coordinating function and the safe-space character of the network for its members.

Item Type: Article
Uncontrolled Keywords: Pricing, reimbursement, drug policy, pharmaceutical preparations, network, collaboration
Subjects: Pharmaoekonomie
Date Deposited: 03 Nov 2026 07:01
Last Modified: 03 Nov 2026 07:01
URI: https://jasmin.goeg.at/id/eprint/5793